Delivery Order SPE2DB22D9367-SPE2DB25FSW77

Award Date 2/20/25
Potential Completion Date 3/13/25
Potential Value $55K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,798.90, is for the delivery of 100 mg vials of the drug Kadcyla. The delivery order is part of a larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, that allows the agency to issue orders for a comprehensive range of...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $15,358.74 and is for the delivery of the pharmaceutical product KADCYLA 100 MG VIALS. The delivery order is part of a larger indefinite delivery contract between DMS Pharmaceutical Group and DLA that has a potential value up to $5 million through December 2025. This contract vehicle allows DLA to procure a...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of KADCYLA 160 MG vials, with a ceiling value of $41,039.20 and a period of performance through July 30, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $39,982.26 contract was awarded by the Defense Logistics Agency (DLA) on July 16, 2024 and has an ultimate completion date of August 6, 2024. The contract is for the delivery of 160 mg vials of the oncology drug Kadcyla. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) that DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $15,358.74 and covers the delivery of Kadcyla 100 mg vials, a specialty oncology medication, with a completion date of August 15, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of 160 mg vials of the oncology drug Kadcyla. The contract is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,623.52 contract is for the delivery of KADCYLA 160 MG vials, a cancer treatment medication, with a completion date of May 24, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $51,195.60, is for the supply of Kadcyla 100 mg vials, a specialty oncology medication. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to $499,999,999 and running...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The order, valued at $10,239.16, is for the supply of 100 mg vials of the oncology medication Kadcyla. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to issue firm fixed-price...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,327.42 contract is for the delivery of 160 mg vials of the oncology drug Kadcyla. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
  • SPE2DB22D9367
    Indefinite Delivery Contract
  • SPE2DB22D9367-SPE2DB25FSW77
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $55,162.88 and an ultimate completion date of March 13, 2025. The contract provides for the delivery of 160 mg vials of the drug KADCYLA to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items. The contract is not associated with any set-aside designation.

Generated 5/22/25, 8:10 PM